Drugs / XW014
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT05579314 Comparator | Sep 2022 → Nov 2024 | type 2 diabetes mellitus | Sciwind Biosciences USA Co., Ltd. | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-10-09 | Hangzhou Sciwind Biosciences Co., Ltd. | Sciwind Biosciences Announces Initiation of Dosing in Phase 1 Clinical Trial Evaluating XW014, an oral small molecule GLP-1 receptor agonist for the Treatment of Obesity and Type 2 Diabetes sciwindbio.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XW014 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05579314 ↗ |
| Route | Oral | “Single oral XW014 administration” NCT05579314 ↗ |